128 related articles for article (PubMed ID: 38300611)
1. Old rivals become new friends.
Rousselot P
Blood; 2024 Feb; 143(5):380-382. PubMed ID: 38300611
[No Abstract] [Full Text] [Related]
2. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
[TBL] [Abstract][Full Text] [Related]
3. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
[TBL] [Abstract][Full Text] [Related]
4. Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
Brivio E; Chantrain CF; Gruber TA; Thano A; Rialland F; Contet A; Elitzur S; Dalla-Pozza L; Kállay KM; Li CK; Kato M; Markova I; Schmiegelow K; Bodmer N; Breese EH; Hoogendijk R; Pieters R; Zwaan CM
Br J Haematol; 2021 Jun; 193(6):1172-1177. PubMed ID: 33529389
[TBL] [Abstract][Full Text] [Related]
5. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Jain N; O'Brien S; Thomas D; Kantarjian H
Front Biosci (Elite Ed); 2014 Jan; 6(1):40-5. PubMed ID: 24389139
[TBL] [Abstract][Full Text] [Related]
6. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Jabbour E; Haddad FG; Short NJ; Senapati J; Jain N; Sasaki K; Jorgensen J; Wang SA; Alvarado Y; Wang X; DiNardo C; Masarova L; Kadia T; Garris RS; Ravandi F; Kantarjian H
Blood; 2024 Feb; 143(5):417-421. PubMed ID: 37879077
[TBL] [Abstract][Full Text] [Related]
8. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
Fujishima N; Uchida T; Onishi Y; Jung CW; Goh YT; Ando K; Wang MC; Ono C; Matsumizu M; Paccagnella ML; Sleight B; Vandendries E; Fujii Y; Hino M
Int J Hematol; 2019 Dec; 110(6):709-722. PubMed ID: 31655984
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
[TBL] [Abstract][Full Text] [Related]
10. Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling.
Hibma JE; Kantarjian HM; DeAngelo DJ; Boni JP
Br J Clin Pharmacol; 2019 Mar; 85(3):590-600. PubMed ID: 30536405
[TBL] [Abstract][Full Text] [Related]
11. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
Cassaday RD; Marks DI; DeAngelo DJ; Jabbour EJ; Advani AS; O'Brien S; Wang T; Neuhof A; Vandendries E; Kantarjian HM; Stock W; Stelljes M
Br J Haematol; 2020 Nov; 191(3):e77-e81. PubMed ID: 32805058
[No Abstract] [Full Text] [Related]
12. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.
Jain N; Maiti A; Ravandi F; Konopleva M; Daver N; Kadia T; Pemmaraju N; Short N; Kebriaei P; Ning J; Cortes J; Jabbour E; Kantarjian H
Am J Hematol; 2021 Aug; 96(8):1000-1007. PubMed ID: 33991360
[TBL] [Abstract][Full Text] [Related]
13. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Jabbour EJ; Sasaki K; Ravandi F; Short NJ; Garcia-Manero G; Daver N; Kadia T; Konopleva M; Jain N; Cortes J; Issa GC; Jacob J; Kwari M; Thompson P; Garris R; Pemmaraju N; Yilmaz M; O'Brien SM; Kantarjian HM
Cancer; 2019 Aug; 125(15):2579-2586. PubMed ID: 30985931
[TBL] [Abstract][Full Text] [Related]
14. Successful Salvage of Very Early Relapse in Pediatric Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin and HLA-haploidentical Peripheral Blood Stem Cell Transplantation With Posttransplant Cyclophosphamide.
Abematsu T; Nishikawa T; Nakagawa S; Kodama Y; Okamoto Y; Kawano Y
J Pediatr Hematol Oncol; 2022 Mar; 44(2):62-64. PubMed ID: 33512872
[TBL] [Abstract][Full Text] [Related]
15. Ponatinib, asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia.
Tinajero J; Koller P; Ali H
Leuk Res; 2023 Jun; 129():107299. PubMed ID: 37120933
[No Abstract] [Full Text] [Related]
16. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
17. Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia.
McCall D; Jabbour E; Roth M; Nunez C; Cuglievan B
Pediatr Blood Cancer; 2023 Jan; 70(1):e29939. PubMed ID: 36031729
[TBL] [Abstract][Full Text] [Related]
18. Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.
Papayannidis C; Sartor C; Dominietto A; Zappone E; Arpinati M; Marconi G; Cristiano G; Nanni J; Parisi S; Barbato F; Paolini S; Soverini S; Terragna C; Robustelli V; Testoni N; Chirumbolo G; Curti A; Cavo M; Bonifazi F
Hematol Oncol; 2021 Oct; 39(4):580-583. PubMed ID: 33963566
[No Abstract] [Full Text] [Related]
19. Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases.
Okura M; Ida N; Yamauchi T
Intern Med; 2020 Aug; 59(16):2047-2051. PubMed ID: 32389945
[TBL] [Abstract][Full Text] [Related]
20. Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Proskorovsky I; Vandendries E; Pagé V; Cappelleri JC; Stelljes M
Adv Ther; 2020 Feb; 37(2):958-962. PubMed ID: 31838711
[No Abstract] [Full Text] [Related]
[Next] [New Search]
